Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions

• Published in: ACS nano 2024-06, Vol.18 (22), p.13983-13999
• Main Authors: Anchordoquy, Thomas, Artzi, Natalie, Balyasnikova, Irina V., Barenholz, Yechezkel, La-Beck, Ninh M., Brenner, Jacob S., Chan, Warren C. W., Decuzzi, Paolo, Exner, Agata A., Gabizon, Alberto, Godin, Biana, Lai, Samuel K., Lammers, Twan, Mitchell, Michael J., Moghimi, S. Moein, Muzykantov, Vladimir R., Peer, Dan, Nguyen, Juliane, Popovtzer, Rachela, Ricco, Madison, Serkova, Natalie J., Singh, Ravi, Schroeder, Avi, Schwendeman, Anna A., Straehla, Joelle P., Teesalu, Tambet, Tilden, Scott, Simberg, Dmitri
• Format: Article
• Language: English
• Subjects: Drug Carriers - chemistry; Humans; Liposomes - chemistry; Nanomedicine; Nanoparticles - chemistry; United States
• ISSN: 1936-0851; 1936-086X; 1936-086X
• DOI: 10.1021/acsnano.4c00182

In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop “Mechanisms and Barriers in Nanomedicine” in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.